A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)
This study has been completed.
Sponsor:
Genentech
Information provided by (Responsible Party):
Genentech
ClinicalTrials.gov Identifier:
NCT00473590
First received: May 14, 2007
Last updated: December 13, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This is a randomized, blinded, placebo-controlled, multicenter, Phase II study designed to provide a preliminary assessment of the safety and efficacy of combining bevacizumab with bortezomib in patients with relapsed or refractory multiple myeloma.
| Condition | Intervention | Phase |
|---|---|---|
|
Multiple Myeloma |
Drug: Bevacizumab Drug: Bortezomib Drug: placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind (Investigator) Primary Purpose: Treatment |
| Official Title: | A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma |
Resource links provided by NLM:
Further study details as provided by Genentech:
Primary Outcome Measures:
- Progression-free Survival (PFS) [ Time Frame: From randomization to disease progression or death on study (up to 116 weeks). ] [ Designated as safety issue: No ]Progression-free survival (PFS) was defined as the time from randomization to disease progression or death on study from any cause within 30 days of the last response assessment. Disease progression was determined by the investigator using the International Myeloma Working Group's (IMWG) uniform response criteria. Median PFS was estimated using Kaplan-Meier methodology. For patients who were alive at the time of the analysis and whose disease had not yet progressed, PFS was censored at the time of the last response assessment.
Secondary Outcome Measures:
- Number of Participants With an Overall Response [ Time Frame: From randomization to the end of study (clinical cut-off; up to 116 weeks). ] [ Designated as safety issue: No ]Overall response was defined as a stringent complete response, complete response, very good partial response, or partial response (sCR, CR, VGPR, and PR, respectively) determined on two consecutive assessments ≤ 6 weeks apart and before the initiation of any new anti-tumor therapy, as assessed by the investigator using the International Myeloma Working Group's (IMWG's) uniform response criteria. Patients without a post-baseline response assessment or who died prior to their first scheduled response assessment were considered non-responders.
- Percentage of Participants With an Overall Response [ Time Frame: From randomization to the end of study (clinical cut-off; up to 116 weeks). ] [ Designated as safety issue: No ]Overall response was defined as a stringent complete response, complete response, very good partial response, or partial response (sCR, CR, VGPR, and PR) determined on two consecutive assessments ≤ 6 weeks apart and before the initiation of any new anti-tumor therapy, as assessed by the investigator using the IMWG's uniform response criteria. Patients without a post-baseline response assessment or who died prior to their first scheduled response assessment were considered non-responders.
- Duration of Response [ Time Frame: From randomization to the end of study (clinical cut-off; up to 116 weeks). ] [ Designated as safety issue: No ]Duration of response was defined as the time from the initial response to disease progression or death on study. Disease progression was determined by the investigator using the IMWG's uniform response criteria and defined as an increase of ≥25% from best response in: Serum M-protein and/or Urine M-protein and/or Marrow plasma cells; or new or increased plasmacytomas or bone lesions; or hypercalcemia due to myeloma. Duration of response was estimated using Kaplan-Meier. For patients who had not progressed or died, duration of response was censored at the date of the last response assessment.
- Overall Survival (OS) [ Time Frame: From randomization until death from any cause, up until the end of study (clinical cut-off; up to 116 weeks). ] [ Designated as safety issue: No ]Overall survival was defined as the duration of time from randomization until death from any cause. All deaths were included, whether they occurred on study treatment or following treatment discontinuation. Overall survival was estimated using Kaplan-Meier. For patients who had not died, overall survival was censored at the date that the patient was last known to be alive.
- Number of Participants With Selected Adverse Events (AEs) [ Time Frame: Participants were monitored for AEs from initiation of treatment to 30 days after treatment termination (up to 122 weeks). ] [ Designated as safety issue: No ]Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0. All serious adverse events are listed in the Adverse Event Reporting section.
| Enrollment: | 102 |
| Study Start Date: | May 2007 |
| Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Bortezomib + bevacizumab
Participants received bortezomib 1.3 mg/m^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and bevacizumab 15 mg/kg administered by intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. After completion of 8 cycles, participants could continue to receive bevacizumab as monotherapy until disease progression.
|
Drug: Bevacizumab
15 mg/kg administered by intravenous infusion
Drug: Bortezomib
1.3 mg/m^2 administered by intravenous bolus injection
|
|
Active Comparator: Bortezomib + placebo
Participants received bortezomib 1.3 mg/m^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and placebo intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. At the completion of the 8-cycle treatment phase, participants entered the observation phase until disease progression.
|
Drug: Bortezomib
1.3 mg/m^2 administered by intravenous bolus injection
Drug: placebo
Intravenous repeating dose
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Previously diagnosed with multiple myeloma
- Relapsed or refractory multiple myeloma with disease progression following one to three prior treatment regimens
- Measurable multiple myeloma disease
Exclusion Criteria:
- Grade ≥ 2 peripheral neuropathy
- Use of corticosteroids within 21 days prior to Day 1
- Use of other anti-myeloma therapy within 21 days prior to Day 1
- Intolerance to bortezomib or compounds containing boron
- Life expectancy of < 12 weeks
- Current, recent, or planned participation in an experimental drug study
- Active malignancy other than multiple myeloma within 5 years before screening
- Prior treatment with bevacizumab
- Inadequately controlled hypertension
- Prior history of hypertensive crisis or hypertensive encephalopathy
- New York Heart Association (NYHA) Class II or greater congestive heart failure (CHF)
- Decreased left ventricular function at study entry
- History of myocardial infarction or unstable angina within 6 months prior to Day 1
- History of stroke or transient ischemic attack within 6 months prior to Day 1
- Significant vascular disease or recent peripheral arterial thrombosis within 6 months prior to Day 1
- Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, or anticipation of need for major surgical procedure during the course of the study
- Core biopsy or other minor surgical procedure, including placement of a vascular access device within 7 days prior to Day 1
- History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1
- Serious, non-healing wound, active ulcer, or untreated bone fracture (for pathologic bone fractures consistent with multiple myeloma, patients may be eligible if no treatment is planned)
- Albuminuria
- Known hypersensitivity to any component of bevacizumab
- Pregnancy (positive pregnancy test) or lactation
Contacts and Locations More Information
No publications provided
| Responsible Party: | Genentech |
| ClinicalTrials.gov Identifier: | NCT00473590 History of Changes |
| Other Study ID Numbers: | AVF4064g |
| Study First Received: | May 14, 2007 |
| Results First Received: | March 31, 2011 |
| Last Updated: | December 13, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Genentech:
|
Avastin AMBER Myeloma Velcade |
Additional relevant MeSH terms:
|
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases |
Bevacizumab Bortezomib Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Pharmacologic Actions Growth Inhibitors Antineoplastic Agents Therapeutic Uses Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 22, 2013